{
    "2021-10-25": [
        [
            {
                "time": "2021-10-22",
                "original_text": "NINETE ONE UK LIMITED 10月22日减持2.27万股泰格医药股份，涉资340.81万港元 减持股份",
                "features": {
                    "keywords": [
                        "减持",
                        "泰格医药",
                        "NINETE ONE UK LIMITED"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-10-21",
                "original_text": "NINETE ONE UK LIMITED 10月21日增持2.03万股泰格医药股份，涉资305.05万港元",
                "features": {
                    "keywords": [
                        "增持",
                        "泰格医药",
                        "NINETE ONE UK LIMITED"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-Q3",
                "original_text": "泰格医药前三季度净利18亿元同比增35% 股价涨6.7%",
                "features": {
                    "keywords": [
                        "净利",
                        "同比增长",
                        "股价上涨",
                        "泰格医药"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-10-22",
                "original_text": "泰格医药：曹晓春女士于10月22日将75万股公司股份解除质押",
                "features": {
                    "keywords": [
                        "解除质押",
                        "泰格医药",
                        "曹晓春"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-Q4",
                "original_text": "泰格医药：公司四季度营收情况一般会高于其余几个季度",
                "features": {
                    "keywords": [
                        "四季度",
                        "营收",
                        "泰格医药"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-10",
                "original_text": "浙商证券维持泰格医药买入评级，泰格医药2021Q3业绩点评：景气延续，阶段跃迁，持续推荐！",
                "features": {
                    "keywords": [
                        "买入评级",
                        "浙商证券",
                        "泰格医药",
                        "业绩点评"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-10",
                "original_text": "信达证券发布泰格医药研报，公司点评报告：三季报业绩超预期，公司业务加速恢复",
                "features": {
                    "keywords": [
                        "研报",
                        "信达证券",
                        "泰格医药",
                        "三季报",
                        "业绩超预期"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-10",
                "original_text": "西部证券维持泰格医药买入评级，2021年三季报点评：主营业务加速恢复，季度业绩创新高",
                "features": {
                    "keywords": [
                        "买入评级",
                        "西部证券",
                        "泰格医药",
                        "三季报",
                        "主营业务"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-10",
                "original_text": "光大证券：维持泰格医药(300347.SZ)“买入”评级 Q3主业继续提速 长期业绩发展向好",
                "features": {
                    "keywords": [
                        "买入评级",
                        "光大证券",
                        "泰格医药",
                        "Q3",
                        "主业提速"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-10",
                "original_text": "西南证券维持泰格医药持有评级：业绩增长超预期，国际化值得期待",
                "features": {
                    "keywords": [
                        "持有评级",
                        "西南证券",
                        "泰格医药",
                        "业绩增长",
                        "国际化"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}